TherapeuticsMD, Inc.
TXMD
$2.08
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 82.13% | 71.61% | 75.19% | 156.93% | 53.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.13% | 71.61% | 75.19% | 156.93% | 53.54% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 82.13% | 71.61% | 75.19% | 156.93% | 53.54% |
| SG&A Expenses | 5.71% | 5.50% | -22.88% | -20.92% | -37.19% |
| Depreciation & Amortization | -18.68% | -24.56% | -63.00% | -64.17% | -54.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.40% | 2.59% | -29.45% | -27.89% | -39.32% |
| Operating Income | 42.87% | 32.22% | 64.31% | 60.16% | 55.23% |
| Income Before Tax | 105.36% | 72.13% | 100.25% | 87.55% | 64.72% |
| Income Tax Expenses | 150.79% | 100.00% | -46.51% | -46.51% | -46.51% |
| Earnings from Continuing Operations | 104.02% | 71.76% | 101.84% | 88.75% | 65.49% |
| Earnings from Discontinued Operations | 138.46% | -35.88% | -64.82% | 106.79% | 103.22% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 108.52% | 73.91% | 109.11% | 92.46% | 71.66% |
| EBIT | 42.87% | 32.22% | 64.31% | 60.16% | 55.23% |
| EBITDA | 47.15% | 33.52% | 68.71% | 63.09% | 58.75% |
| EPS Basic | 108.47% | 73.92% | 108.97% | 92.81% | 73.85% |
| Normalized Basic EPS | 124.24% | 55.50% | 104.78% | 86.50% | 87.45% |
| EPS Diluted | 104.69% | 67.91% | 106.09% | 91.82% | 73.30% |
| Normalized Diluted EPS | 124.02% | 55.50% | 104.78% | 86.50% | 87.45% |
| Average Basic Shares Outstanding | 0.32% | 0.32% | 1.30% | 3.09% | 6.10% |
| Average Diluted Shares Outstanding | 0.47% | 0.32% | 1.30% | 3.09% | 6.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |